earnings
confidence high
sentiment positive
materiality 0.75
Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive
Edgewise Therapeutics, Inc.
2021-FY EPS reported
-$1.14
- Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).
- Cash, equivalents & marketable securities $281M as of Dec 31, 2021.
- Phase 1b EDG-5506 in BMD: CK reduced 71%, TNNI2 reduced 83%; well-tolerated.
- Phase 2 trials planned: BMD in H1 2022, DMD in H2 2022; ARCH open-label study ongoing.
- R&D expenses $32.2M in 2021 (vs $15.0M in 2020); G&A $11.0M (vs $2.2M).